


## AMENDMENTS TO THE CLAIMS

Claims 3-5 and 22 have been amended below.

1. (Original): A compound of the formula (I):



wherein

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are, independently of one another, alkyl residues with 1 to 6 carbon atoms;

or a physiologically tolerated salt thereof,

or a derivative thereof,

or a stereoisomeric form of:

a compound of formula (I) as described above,

or a physiologically tolerated salt of a compound of formula (I) as described above,

or a derivative of a compound of formula (I) as described above

or a tautomeric form of:

a compound of formula (I) as described above,

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

or a physiologically tolerated salt of a compound of formula (I) as described above,

or a derivative of a compound of formula (I) as described above.

2. (Original): The compound of formula (I) as claimed in claim 1, wherein one, two, three, or all of R<sub>1</sub> to R<sub>4</sub> are butyl residues, and wherein any of the butyl residues may be straight-chain or branched,

or a physiologically tolerated salt thereof,

or a derivative thereof,

or a stereoisomeric form of:

the compound of formula (I) as described above in this claim,

or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,

or a derivative of the compound of formula (I) as described above in this claim,

or a tautomeric form of:

the compound of formula (I) as described above in this claim,

or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,

or a derivative of the compound of formula (I) as described above in this claim.

3. (Currently amended): The compound of formula (I) as claimed in claim 1, wherein R<sub>1</sub> to R<sub>4</sub> ~~comprise~~ are, in any combination, three butyl residues and one propyl residue, and wherein any of the alkyl residues may be straight-chain or branched,

or a physiologically tolerated salt thereof,

or a derivative thereof,

or a stereoisomeric form of:

the compound of formula (I) as described above in this claim,

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,

or a derivative of the compound of formula (I) as described above in this claim,

or a tautomeric form of:

the compound of formula (I) as described above in this claim,

or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,

or a derivative of the compound of formula (I) as described above in this claim.

4. (Currently amended): The compound of formula (I) as claimed in claim 1, wherein R<sub>1</sub> to R<sub>4</sub> ~~comprise~~ are, in any combination: two butyl and two propyl residues, or one butyl, one pentyl, one ethyl, and one propyl residue, and wherein any of the alkyl butyl, propyl, or pentyl residues may be straight-chain or branched,

or a physiologically tolerated salt thereof,

or a derivative thereof,

or a stereoisomeric form of:

the compound of formula (I) as described above in this claim,

or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,

or a derivative of the compound of formula (I) as described above in this claim,

or a tautomeric form of:

the compound of formula (I) as described above in this claim,

or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,

or a derivative of the compound of formula (I) as described above in this claim.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

5. (Currently amended): The compound of formula (I) as claimed in claim 1, wherein R<sub>1</sub> to R<sub>4</sub> ~~comprise~~ are, in any combination: four butyl residues or two butyl, one propyl and one pentyl residue, and wherein any of the alkyl residues may be straight-chain or branched,

or a physiologically tolerated salt thereof,

or a derivative thereof,

or a stereoisomeric form of:

the compound of formula (I) as described above in this claim,

or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,

or a derivative of the compound of formula (I) as described above in this claim,

or a tautomeric form of:

the compound of formula (I) as described above in this claim,

or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,

or a derivative of the compound of formula (I) as described above in this claim.

6. (Original): A mixture comprising two or more isomers of a compound of formula (I) as claimed in claim 1.

7. (Original): A mixture comprising two or more isomers of a compound of formula (I) as claimed in claim 2.

8. (Original): A mixture comprising two or more isomers of a compound of formula (I) as claimed in claim 3.

9. (Original): A mixture comprising two or more isomers of a compound of formula (I) as claimed in claim 4.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

10. (Original): A mixture comprising two or more isomers of a compound of formula (I) as claimed in claim 5.

11. (Original): A compound of the formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 1, obtainable by cultivation of Streptomyces sp. ST 101396 (DSM 13309) or by cultivation of one of the variants or mutants of DSM 13309.

12. (Original): A compound of the formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 2, obtainable by cultivation of Streptomyces sp. ST 101396 (DSM 13309) or by cultivation of one of the variants or mutants of DSM 13309.

13. (Original): A compound of the formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 3, obtainable by cultivation of Streptomyces sp. ST 101396 (DSM 13309) or by cultivation of one of the variants or mutants of DSM 13309.

14. (Original): A compound of the formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 4, obtainable by cultivation of Streptomyces sp. ST 101396 (DSM 13309) or by cultivation of one of the variants or mutants of DSM 13309.

15. (Original): A compound of the formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 5, obtainable by cultivation of Streptomyces sp. ST 101396 (DSM 13309) or by cultivation of one of the variants or mutants of DSM 13309.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

16. (Original): A process for the production of a compound of formula (I), or a salt or a derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 1, comprising

cultivating *Streptomyces* sp. ST 101396 (DSM 13309) or one of its variants or mutants,

isolating and purifying one or more target compounds, and

optionally converting said target compound into a physiologically tolerated salt or derivative.

17. (Original): The process as claimed in claim 16, wherein the cultivation is carried out at a temperature in the range between about 20°C and about 35°C and a pH in the range between about 5 and about 8.

18. (Original): A pharmaceutical composition comprising an effective amount of at least one compound of formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 1, and a pharmaceutically acceptable carrier.

19. (Original): A method for reducing the activity of a neurotensin receptor comprising administering to a patient in need thereof at least one compound of formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 1.

20. (Original): A method for treating a disease comprising administering to a patient in need thereof at least one compound of formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 1,

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

wherein the disease is chosen from schizophrenia, Parkinson's disease, and Alzheimer's disease.

21. (Original): A method for the production of a pharmaceutical composition, comprising mixing at least one compound of formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 1, and suitable excipients and/or carriers, and converting the mixture into a suitable dosage form.

22. (Currently amended): Isolated Streptomyces species ST 101396 (DSM 13309).

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER <sup>LLP</sup>

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com